Key clinical point: People with RA or spondyloarthritis can be kept on immunosuppressive medications, including tumor necrosis factor inhibitors and other biologics, if they develop COVID-19.

Major finding: Patients on biologic or targeted synthetic disease-modifying antirheumatic drugs for RA or spondyloarthritis did not fare worse with COVID-19, compared with the general population.

Study details: A case series of eight patients with confirmed or suspected COVID-19, and five asymptomatic patients with likely exposure, from a rheumatology treatment center in Italy.

Disclosures: Dr. Monti and colleagues reported no outside funding or financial conflicts of interest.